Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

With DIVISLAB's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.000000
forwardPE 53.788498
debtToEquity 0.584000
earningsGrowth -0.010000
revenueGrowth 0.123000
grossMargins 0.616540
operatingMargins 0.296470
trailingEps 93.110000
forwardEps 116.958090

DIVISLAB's forward PE being elevated could limit price appreciation and heighten the risk of a correction. Investors need to carefully assess this parameter in combination with other fundamentals to determine whether the stock is overvalued.
Positive gross and operating margins for Divi's Laboratories Limited suggest that the company is operating profitably. These margins highlight Divi's Laboratories Limited's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
Divi's Laboratories Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Divi's Laboratories Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Price projections for DIVISLAB have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in DIVISLAB's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


DIVISLAB experienced 8 sell transactions with market price of 6399.481262207031 per share.The period under consideration saw no sell transactions.More buys than sells have been occurring around the current price levels of Divi's Laboratories Limited, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


Analysts have shown a buy bias for DIVISLAB, marking it as a favorable investment option. This could inspire investors to see DIVISLAB as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.